BioSig Lands Licensing Deal with Mayo Clinic

The new agreement aims to develop a new product pipeline to support some of the more advanced features of BioSig’s Pure EP System.

Amanda Pedersen

September 13, 2019

1 Min Read
BioSig Lands Licensing Deal with Mayo Clinic
A new licensing agreement between BioSig Technologies and Mayo Clinic will seek to significantly advance current arrhythmia treatments.BioSig Technologies Inc.

BioSig Technologies and Mayo Clinic have joined forces once again, this time to develop a new product pipeline to support some of the more advanced features of BioSig's Pure EP System.

Samuel Asirvatham, MD, Mayo Clinic's vice-chair of innovation and medical director of the electrophysiology (EP) laboratory, will lead the new development program. The company previously signed a 10-year collaboration agreement with Mayo Clinic in March 2017.

"The new product that we intend to develop under the latest licensing will seek to significantly advance the current arrhythmia treatments," said Kenneth Londoner, BioSig's CEO and chairman. "It will be an exciting journey, and we look forward to reporting on our progress.”

BioSig's Pure EP System is intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing EP procedures. BioSig says its ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias such as atrial fibrillation and ventricular tachycardia.

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like